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The Epstein-Barr virus (EBV) oncoprotein LMP1 (latent
membrane protein 1) mimics a constitutively active recep-
tor molecule. It contributes to viral cell transformation by
the activation of NF-kappaB, JNK/AP1, MAPK, JAK/STAT
and PI3-kinase signaling. LMP1 recruits TRAF1-3, 5 and 6,
TRADD and RIP1, which are also known as signaling
mediators of Toll-like and tumor necrosis factor-recep-
tors. Here, we established a functional proteomics
approach to identify novel interaction partners of the
LMP1 signaling domain. This approach led to the charac-
terization of the tyrosine phosphatase SHP1 as a direct
binding partner of LMP1. Interaction of SHP1 with LMP1
was verified in primary human B-cells, which had been
transformed with a recombinant EBV carrying a HA-
tagged LMP1 allele. The SHP1 binding site of LMP1 is
located within the membrane-proximal region of the
LMP1 signaling domain and shows no overlap with
known protein interaction domains of LMP1. The unique
sequence of this site does not resemble known SHP1
interaction motifs of cellular proteins. Mutation of the
SHP1 site caused the loss of SHP1 binding to LMP1 in
EBV-transformed human B-cells. SHP1 has previously
been described as a negative regulator of growth factor or
immune receptor signaling by dephosphorylating e.g.
tyrosine kinases such as JAKs or SRC kinases. LMP1 induc-
tion of the NF-kappaB pathway was greatly enhanced in
SHP1-knockout DT40 B-cells as compared to wildtype
cells. This effect was reverted by reconstitution of SHP1
expression in the SHP1-KO cells. Also mutation of the
SHP1 interaction site or the co-expression of a dominant-
negative SHP1 caused hyperactivation of NF-kappaB sign-
aling and JAK3 hyperphosphorylation by LMP1. Because
the SHP1 interaction site of LMP1 mediates inhibitory
effects on LMP1 signaling, we named this region CTIR1
(C-terminal inhibitory region 1). In summary, the pro-
teomic analysis of the LMP1 complex revealed a novel
autoregulatory mechanism of oncogenic LMP1 signaling,
which limits its own activity through the recruitment of a
tyrosine phosphatase. This mechanism might be of high
relevance for the survival of EBV-transformed cells
because LMP1 hyperactivity is known to be toxic for the
target cells.
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